DOCSLIB.ORG

Combination of Xenon and Isoflurane Produces a Synergistic Protective

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combination of Xenon and Isoflurane Produces a Synergistic Protective Ⅵ LABORATORY REPORT Anesthesiology 2003; 99:748–51 © 2003 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Combination of Xenon and Isoflurane Produces a Synergistic Protective Effect against Oxygen–Glucose Deprivation Injury in a Neuronal–Glial Co-culture Model Daqing Ma, M.D., Ph.D.,* Mahmuda Hossain, Ph.D.,† Nishanthan Rajakumaraswamy, B.Sc.,‡ Nicholas P. Franks, Ph.D.,§ Mervyn Maze, FRCP, FRCA, FMedSci࿣ SUSTAINED exposure to glutamate causes neuronal combination, their efficacy would be enhanced. To test death by overactivation of its receptors, particularly our hypothesis, we studied the neuroprotective effect of 1,2 Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/99/3/748/337011/0000542-200309000-00034.pdf by guest on 27 September 2021 those of the N-methyl-D-aspartate (NMDA) subtype. the combination of xenon and isoflurane versus oxygen– This process, denoted by the term excitotoxicity, is be- glucose deprivation (OGD) injury in a neuronal–glial lieved to play an important role in ongoing neuronal co-culture model. injury and death in acute insults, such as ischemic stroke and head trauma.3,4 Consequently, the neuroprotective effects of NMDA receptor antagonists, including xenon, Materials and Methods have been investigated in a variety of both in vitro and in vivo models of neuronal injury5–9 of the type that may The methodology for preparing mixed cortical cell occur perioperatively.10 Notwithstanding their putative cultures containing both neuronal and glial cell elements beneficial effects, the clinical use of NMDA antagonists from mice has been reported elsewhere.5 Before OGD has been hindered11 by the observation that several exposure, the cell cocultures were carefully washed drugs of this class of compound produce neurotoxicity, twice with HEPES buffer, after which prewarmed characterized by distinctive behavioral and morphologic (37°C), deoxygenated balanced salt solution containing effects. Although xenon does not seem to have this side (in mM): 116 NaCl, 5.4 KCl, 0.8 MgSO4, 1.0 NaH2PO4, 8 effect, it may be desirable to use lower concentrations 1.8 CaCl2, and 26 NaHCO3, pH 7.4, was added into each because of the prohibitive cost of this gas and to permit well, and the plates were placed in a temperature-con- adequate oxygenation. Therefore, we sought to investi- trolled anaerobic chamber for 75 min at 37°C. Pilot gate whether neuroprotective efficacy can be observed studies showed that the maximal neuronal injury could when this NMDA receptor antagonist is combined with be achieved by OGD for between 60 and 100 min. OGD another putative neuroprotective agent that acts by mod- was terminated by washing with Eagle’s minimal essen- ulating the ␥-aminobutyric acid (GABA) receptor. The tial medium enhanced with 25 mM glucose and 38 mM neuronal damage from ischemia may also be a result of NaHCO3, and the culture plates were returned to nor- loss of inhibitory influences. In the brain, GABA acts as moxic conditions containing a minimum of 20% O2 for the major inhibitory neurotransmitter; an agonist of the 6 h at 37°C. The balance of the gas mixture depended on A subtype of the GABA receptor (GABAA) has been the experimental group. Culture media for the OGD and shown to be neuroprotective in a transient forebrain the 6 h post-OGD periods were prepared by bubbling 12 ischemia model. Isoflurane potentiates activation of pure gases (O2,N2,CO2, xenon, or isoflurane) through 13 the GABAA receptors, and its neuroprotective effect fine sintered-glass bubblers in Drechsel bottles filled has been demonstrated previously.14–18 Because these with either balanced salt solution or Eagle’s minimal anesthetics exert their neuroprotectant properties essential medium for 20 min, a period that was found to through different mechanisms, we hypothesized that in be sufficient to allow equilibration as assessed by gas chromatography. For each set of experimental condi- tions, flow rates of gases were adjusted so that the gas * Lecturer, Department of Anaesthetics and Intensive Care, Imperial College, concentrations in the solutions were equivalent to the † Research Assistant, Department of Anaesthetics and Intensive Care, Imperial College, ‡ Medical Student, University College, § Professor of Biophysics and corresponding gas composition in a purpose-built air- Anaesthetics, Departments of Biological Sciences and Anaesthetics and Intensive tight, temperature-controlled cell-culture chamber Care, Imperial College, ࿣ Sir Ivan Magill Professor of Anaesthetics, Departments of Anaesthetics and Intensive Care and Biological Sciences, Imperial College. equipped with inlet and outlet valves and an internal 9 Received from the Magill Department of Anaesthesia, Chelsea & Westminster electric fan (as described previously ). Total gas flow Hospital, Imperial College of Science, Technology and Medicine, London, United was 100 ml/min, and the chamber was flushed for 40 Kingdom. Submitted for publication January 8, 2003. Accepted for publication April 30, 2003. Supported by the Medical Research Council and the Joint min before a closed system was established. With the Research Committee of the Chelsea and Westminster NHS HealthCare Trust, above-mentioned protocol, the final gas concentrations London, United Kingdom. Address reprint requests to Dr. Maze: Magill Department of Anaesthesia, (determined by use of gas chromatography) were found Chelsea & Westminster Hospital, Imperial College of Science, Technology and to be stable, and there was no measurable leakage over Medicine, 369 Fulham Road, London SW10 9NH, United Kingdom. Address electronic mail to: [email protected]. Individual article reprints may be purchased 24 h. For the delivery of isoflurane, a Cyprane isoflurane through the Journal Web site, www.anesthesiology.org. vaporizer (AE Service and Supplies Ltd., Keighley, United Anesthesiology, V 99, No 3, Sep 2003 748 LABORATORY REPORT 749 Kingdom) was used; because this vaporizer is not cali- brated to operate at these low flow rates, we monitored isoflurane concentration (Datex-Engstrom AS/3; Instru- mentarium Corp, Helsinki, Finland) continuously to es- tablish that the appropriate concentration was being delivered. Neuronal injury was assessed by lactate dehy- drogenase (LDH) released into the medium, as previ- ously described.9 The data were fitted to a logistic equa- tion of the form: ␣n ͑ ͒ ϭ E c , Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/99/3/748/337011/0000542-200309000-00034.pdf by guest on 27 September 2021 ␣n ϩ cn where E(c) is the LDH release expressed as a fraction of the control at a xenon or isoflurane concentration c, ␣ is the IC50, and n is a slope factor. The results are ex- Ϯ pressed as mean SEM. The IC50 value is defined as the concentration of xenon or isoflurane that reduced the LDH release to 50% of the maximal value in control OGD exposures (i.e., in the absence of either anesthetic). To determine whether or not the combined effects of xenon and isoflurane were additive when administered as a mixture, we compared the observed IC50 value for the mixture with that predicted assuming additivity. In general, for additivity, the following condition holds: a b ϩ ϭ 1, 1 Ϫ E͑c ͒ 1/na 1 Ϫ E͑c ͒ 1/nb Fig. 1. Xenon and isoflurane alone and in combination inhib- ␣ ͩ a ͪ ␣ ͩ b ͪ ited lactate dehydrogenase (LDH) release, expressed as a frac- a ͑ ͒ b ͑ ͒ E ca E cb tion of the maximum LDH release in the absence of agents or 4) induced by 75 min oxygen–glucose 3 ؍ mean ؎ SEM, n) where a and b are the concentrations of xenon and deprivation. The values for control LDH release in this series of isoflurane, respectively, that are present in a mixture, experiments were in the range between 327 and 380 Berger- xenon alone, 35.9 ؎ 2.2% ؍ Broida units/ml. (A) Closed circles ␣ ␣ ؍ ؍ and a and b are the IC50 concentrations of xenon and atm; open circles in the present of 0.6% isoflurane, IC50 ؍ ؍ ؎ isoflurane when applied alone, with associated slope 18.9 2.5% atm. (B) Closed circles isoflurane alone, IC50 ,in the presence of 14% xenon ؍ open circles ;0.35% ؎ 2.72 factors na and nb. For the special case of 50% inhibition .%0.13 ؎ %0.92 ؍ IC of LDH release (i.e.,Eϭ 0.5), this equation reduces to: 50 a b values (mean Ϯ SEM) were 35.9 Ϯ 2.2% atm for xenon ϩ ϭ ␣ ␣ 1. and 2.72 Ϯ 0.35% atm for isoflurane. We next deter- a b mined the effects of a low concentration of one agent on ␣ ␣ Thus, having determined a and b from the concentra- the concentration–response curve for the other agent. In tion–response curves of each agent individually, the con- the presence of 0.6% isoflurane, the concentration–re- centration of a (xenon) in the presence of a fixed con- sponse curve for xenon was changed significantly (fig. centration of b (isoflurane), or vice versa, to achieve a 1A), and the IC50 value for xenon-mediated neuroprotec- 50% reduction in LDH release from the control value can tion decreased to 18.9 Ϯ 2.5% atm, which is significantly be predicted, assuming that additivity holds. This pre- Ϯ Ͻ lower than 28 2.0% atm (P 0.05), the predicted IC50 dicted value can then be compared with the observed value for xenon in the presence of 0.6% isoflurane, value. Statistical significance was assessed by use of the assuming that the effects of isoflurane and xenon are Student t test with Bonferroni correction for multiple additive (see Materials and Methods). Similarly, in the Ͻ comparisons. A value of P 0.05 was considered to be presence of 14% xenon, the concentration–response statistically significant. curve for isoflurane was changed significantly (fig. 1B), Ϯ with the IC50 value being decreased to 0.92 0.13% Ͻ Ϯ Results (P 0.05), which is significantly lower than 1.66 0.22% atm, the predicted IC50 value for isoflurane, as- Neuronal damage induced by a 75-min duration of suming additivity.
Load more

Recommended publications
  • First Xenon-Xenon Collisions in the Lhc
    9th International Particle Accelerator Conference IPAC2018, Vancouver, BC, Canada JACoW Publishing ISBN: 978-3-95450-184-7 doi:10.18429/JACoW-IPAC2018-MOPMF039 FIRST XENON-XENON COLLISIONS IN THE LHC M. Schaumann∗, R. Alemany-Fernandez, P. Baudrenghien, T. Bohl, C. Bracco, R. Bruce, N. Fuster-Martinez, M. A. Jebramcik, J.M. Jowett, T. Mertens, D. Mirarchi, S. Redaelli, B. Salvachua, M. Solfaroli, H. Timko, J. Wenninger, CERN, Geneva, Switzerland Abstract EXECUTION OF THE RUN In 2017, the CERN accelerator complex once again demonstrated its flexibility by producing beams of a new A total of about 18 h of LHC time were taken for the Xe ion species, xenon, that were successfully injected into LHC. collision run. The schedule was designed to include set-up, On 12 October, collisions of fully stripped xenon nuclei first injection, validation and physics data taking. A further 12 h were devoted to experiments on crystal collimation, de- were recorded for the first time in the LHC√ at a centre-of- scribed elsewhere [3]. This tight schedule was only feasible mass energy per colliding nucleon pair of sNN = 5.44 TeV. Physics data taking started 9.5hafter the first injection of by drastically reducing the complexity of the set-up follow- xenon beams and lasted a total of 6h. The integrated lumi- ing the model of the p–Pb pilot run in September 2012 [4,5] nosity delivered to the four LHC experiments was sufficient when first injection, validation and physics data-taking were that new physics results can be expected soon. We provide achieved within a single fill.
    [Show full text]
  • XENON X-1100 High-Intensity Pulsed Light System
    XENON X-1100 High-Intensity Pulsed Light System The low cost R&D tool for investigating the applicability of Pulsed Light for new and emerging applications. The tool that researchers, scientists and engineers have been looking for is here. An easy-to-use photonic system developed by XENON that will open new doors and lead to new discoveries. The power of Pulsed Light In virtually all disciplines of science and technology there are applications where precise delivery of energy is demanded. One less studied energy delivery mechanism is the use of high-intensity pulsed light. At present the most prevalent example of this is in the use of lasers. However, the point source, coherent and single wavelength nature of lasers, are often not suited to the majority of challenges facing many industries. In these situations, it is crucial to have a broad spectra source so as not to be restricted in choosing materials with specific absorption characteristics. Because XENON sources generate light which extends from the deep UV to IR and often with peak pulse powers measured in megawatts, the ability of these sources to perform tasks such as breaking chemical bonds, sintering, ablating or sterilizing is highly realizable. The high peak powers generated by XENON’s production level systems are possible by tightly controlling the pulse durations measured from a few microseconds to milliseconds. Until now there was no practical method of generating this intense pulsed light in a low-cost R&D tool that was safe, compact and versatile. XENON has developed a system to address this challenge based on over 50 years of exper- tise in the Pulsed Light industry.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Xenon Gas Xe Safety Data Sheet SDS P4677
    Xenon Safety Data Sheet P-4677 This SDS conforms to U.S. Code of Federal Regulations 29 CFR 1910.1200, Hazard Communication. Date of issue: 01/01/1979 Revision date: 10/24/2016 Supersedes: 10/02/2014 SECTION: 1. Product and company identification 1.1. Product identifier Product form : Substance Name : Xenon CAS No : 7440-63-3 Formula : Xe Other means of identification : Xenon 1.2. Relevant identified uses of the substance or mixture and uses advised against Use of the substance/mixture : Industrial use. Use as directed. 1.3. Details of the supplier of the safety data sheet Praxair, Inc. 10 Riverview Drive Danbury, CT 06810-6268 - USA T 1-800-772-9247 (1-800-PRAXAIR) - F 1-716-879-2146 www.praxair.com 1.4. Emergency telephone number Emergency number : Onsite Emergency: 1-800-645-4633 CHEMTREC, 24hr/day 7days/week — Within USA: 1-800-424-9300, Outside USA: 001-703-527-3887 (collect calls accepted, Contract 17729) SECTION 2: Hazard identification 2.1. Classification of the substance or mixture GHS-US classification Compressed gas H280 2.2. Label elements GHS-US labeling Hazard pictograms (GHS-US) : GHS04 Signal word (GHS-US) : WARNING Hazard statements (GHS-US) : H280 - CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED OSHA-H01 - MAY DISPLACE OXYGEN AND CAUSE RAPID SUFFOCATION Precautionary statements (GHS-US) : P202 - Do not handle until all safety precautions have been read and understood P271+P403 - Use and store only outdoors or in a well-ventilated place CGA-PG05 - Use a back flow preventive device in the piping CGA-PG10 - Use only with equipment rated for cylinder pressure CGA-PG06 - Close valve after each use and when empty CGA-PG02 - Protect from sunlight when ambient temperature exceeds 52°C (125°F) 2.3.
    [Show full text]
  • Lung Ventilation - Xenon
    Lung Ventilation - Xenon Special Instructions Patients with severe dyspnea may not be able to tolerate this examination. To be performed only at UNMH. Radiopharmaceutical: Xe-133 gas Dose (Adult/Pediatric): Refer to Nuclear Medicine Dose Chart Route of Administration: Inhalation from a Xe-133 gas delivery system. Patient Preparation: None. Equipment Setup: Gamma Camera: ZOOM as appropriate for small children Collimator: Orbiter: LEAP SPECT-CT/ECAM/Evo/Symbia E: High resolution Computer setup: • Static acquisition • 128 x 128 matrix • Zoom 1.0 (greater for small children)—ensure that the lungs fill a significant portion of the detector for small patients • 10 sec/image for inspiration • 30 sec/image for all other images Patient Positioning: Orbiter: • Seated upright on a stool (preferred) with the detector posterior to the patient. Supine if necessary All others: • Supine Procedure: • If the patient is able to sit upright on a stool for the examination, perform the ventilation portion of the examination on the Orbiter if available. • Before beginning the study, explain the breathing maneuvers required; the patient should rehearse these maneuvers. • Place the mask on the patient and ensure that it fits snugly. • Inspiration (Single-breath) Image: • Instruct the patient to exhale completely and then to take a deep breath as the Xe-133 gas flows in. • The patient should hold his/her breath for 10 sec (if possible) while posterior (and anterior if on a dual-headed camera) imaging is performed. Revised 2017-01 Lung Ventilation - Xenon (continued) • Equilibrium (Rebreathing/Wash-in) Images: • The patient should then breathe normally for 3 images (90 seconds).
    [Show full text]
  • Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
    FDA Established Pharmacologic Class (EPC) Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for [indication(s)].” For Active Moiety Name each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13. .alpha.
    [Show full text]
  • Pharmacokinetics and Pharmacology of Drugs Used in Children
    Drug and Fluid Th erapy SECTION II Pharmacokinetics and Pharmacology of Drugs Used CHAPTER 6 in Children Charles J. Coté, Jerrold Lerman, Robert M. Ward, Ralph A. Lugo, and Nishan Goudsouzian Drug Distribution Propofol Protein Binding Ketamine Body Composition Etomidate Metabolism and Excretion Muscle Relaxants Hepatic Blood Flow Succinylcholine Renal Excretion Intermediate-Acting Nondepolarizing Relaxants Pharmacokinetic Principles and Calculations Atracurium First-Order Kinetics Cisatracurium Half-Life Vecuronium First-Order Single-Compartment Kinetics Rocuronium First-Order Multiple-Compartment Kinetics Clinical Implications When Using Short- and Zero-Order Kinetics Intermediate-Acting Relaxants Apparent Volume of Distribution Long-Acting Nondepolarizing Relaxants Repetitive Dosing and Drug Accumulation Pancuronium Steady State Antagonism of Muscle Relaxants Loading Dose General Principles Central Nervous System Effects Suggamadex The Drug Approval Process, the Package Insert, and Relaxants in Special Situations Drug Labeling Opioids Inhalation Anesthetic Agents Morphine Physicochemical Properties Meperidine Pharmacokinetics of Inhaled Anesthetics Hydromorphone Pharmacodynamics of Inhaled Anesthetics Oxycodone Clinical Effects Methadone Nitrous Oxide Fentanyl Environmental Impact Alfentanil Oxygen Sufentanil Intravenous Anesthetic Agents Remifentanil Barbiturates Butorphanol and Nalbuphine 89 A Practice of Anesthesia for Infants and Children Codeine Antiemetics Tramadol Metoclopramide Nonsteroidal Anti-infl ammatory Agents 5-Hydroxytryptamine
    [Show full text]
  • Xenon-Tried-Tested-And-True.Pdf
    Tried, tested and true: Why Xenon illumination is the preferred choice over laser phosphor for mainstream cinema Xenon – cinema’s workhorse With 45 years of use and 1.5 million installations worldwide, Christie® Xenolite® lamps are a constant in the cinema industry. Producing impressive light output, accurate color reproduction and boasting 99.999% reliability, this “lightning in a bottle” technology is the dependable workhorse trusted by exhibitors everywhere. Laser phosphor cinema projectors – not to be confused with RGB laser projectors – have been touted as a viable option to replace Xenon-based systems. This has resulted in cinema owners being faced with a decision. Should they continue using Xenon lamps, or make the switch to laser phosphor? Our answer to this is simple. For mainstream theatres, laser phosphor cinema projectors do not provide the performance advantages to justify them as an acceptable option over Xenon-based systems. Brightness over 30,000 hours 20K lumen-class, Xenon versus laser phosphor* 110% (Number of lamps used) (14 fL) 100% 1 2 3 4 5 6 7 8 9 10 11 Xenon 90% 11 fL typical (11 fL) 80% â Below DCI standards Just over 1 year á 70% of operation (based on 10 hours per day) 60% DCI Laser phosphor 7.0 fL typical ed brightness 50% ent of rc quir Pe re 0% 052,800 ,600 8,400 11,200 14,000 16,800 19,600 22,400 25,200 28,000 30,800 Hours of operation * ~20m wide screen * ~1.8 gain screen Laser phosphor – not suitable for cinema laser phosphor projectors.
    [Show full text]
  • Coordination Chemistry of Xenon
    Coordination Chemistry of Xenon Paul Griffin Literature Seminar 11/14/19 Situated on the far side of the periodic table, the chemical inertness of the noble gases has led to their widespread applications ranging from gas-discharge lamps and ion engines for space travel to medical applications including as MRI contrast agents and radiotherapy.1 Though all practical applications of the noble gases center around Xe (0), understanding the reactivity and bonding of xenon in higher oxidation states is fundamental to investigating chemistry at the far end of the periodic table. The reactivity of the noble gases, in particular xenon, was first uncovered when Bartlett, who had previously prepared dioxygenyl hexafluoroplatinate (V) (O2PtF6), noted similar ionization energies for molecular oxygen and atomic xenon (a difference of 0.1 eV).2 Mixing of xenon with PtF6 vapor led to the formation of an orange-yellow solid led to the synthesis of the first noble gas compound, xenon hexafluoroplatinate (V) (XePtF6). The chemistry of xenon has evolved significantly since its’ discovery to include an assortment of xenon fluorides, oxides, oxylfluorides, organoxenon3, and metalloxenon compounds such as the tetraxenoaurate (II) cation (Figure 1).4 These species have weak covalent bonding between Xe and the oxygen/fluorine moieties.5 The chemistry of xenon is dominated by the 2+, 4+, and 6+ oxidation states, though Xe (VIII) compounds are known in the form of perxenates and xenon tetroxide. These primarily ionic species, particularly the oxides, oxylfluorides, and fluorides, serve as precursors to noncovalent adducts of xenon. Figure 1. Organoxenon and metalloxenon species Recent work has led to the preparation of xenon adducts with noncovalently interacting ligands such as acetonitrile6a, 6b, ketones6c, sulfoxides6c, and crown ethers6d (Figure 2) capable of weakly coordinating to xenon salts to afford stable species at room temperature.
    [Show full text]
  • Dual Antidepressant Duloxetine Blocks Nicotinic Receptor Currents, Calcium Signals and Exocytosis in Chromaffin Cells Stimulated with Acetylcholine S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/07/13/jpet.118.250969.DC1 1521-0103/367/1/28–39$35.00 https://doi.org/10.1124/jpet.118.250969 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 367:28–39, October 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Dual Antidepressant Duloxetine Blocks Nicotinic Receptor Currents, Calcium Signals and Exocytosis in Chromaffin Cells Stimulated with Acetylcholine s Carmen Nanclares, Isabel Gameiro-Ros, Iago Méndez-López, Carmen Martínez-Ramírez, J. Fernando Padín-Nogueira, Inés Colmena, Andrés M. Baraibar, Luis Gandía,1 and Antonio G. García1 Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Downloaded from Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.) Received May 28, 2018; accepted July 12, 2018 ABSTRACT jpet.aspetjournals.org The inhibition of nicotinic acetylcholine receptors (nAChRs) partially use dependent. The ACh-elicited membrane depolar- 21 has been proposed as a potential strategy to develop new antide- ization, the elevation of cytosolic calcium ([Ca ]c), and cate- pressant drugs. This is based on the observation that antide- cholamine release in BCCs were also blocked by duloxetine. This pressants that selectively block noradrenaline (NA) or serotonin blockade developed slowly, and the recovery of secretion was (5-HT) reuptake also inhibit nAChRs.
    [Show full text]
  • Pamphlet 155-2 Appendix 1 Data Code Values
    Florida Department of Children and Families Substance Abuse and Mental Health Financial and Services Accountability Management System (FASAMS) Pamphlet 155-2 Appendix 1 Data Code Values Last Revision Date: 7/22/2021 Version 13.0 Pamphlet 155-2 Appendix 1, Version 13.0 Last Revision Date 7/22/2021 Page 1 of 71 Table of Contents 1 Children Dependency or Delinquency Status ................................................................................................................. 3 2 County Area .................................................................................................................................................................... 4 3 Covered Service or Project .............................................................................................................................................. 5 4 Discharge Destination ................................................................................................................................................... 18 5 Education Grade Level .................................................................................................................................................. 19 6 Employment Status ....................................................................................................................................................... 19 7 Evaluation Level ............................................................................................................................................................ 20 8 Project Codes
    [Show full text]
  • Sevoflurane, Desflurane, and Xenon New Inhaled Anesthetics in Veterinary Medicine
    Ciência Rural, Santa Maria, v.31, n.1, p.177-183, 2001 177 ISSN 0103-8478 SEVOFLURANE, DESFLURANE, AND XENON NEW INHALED ANESTHETICS IN VETERINARY MEDICINE SEVOFLURANO, DESFLURANO E XENÔNIO NOVOS ANESTÉSICOS INALATÓRIOS EM MEDICINA VETERINÁRIA Cláudio Correa Natalini 1 - REVIEW - SUMMARY relação ao uso clínico e a segurança do uso desses novos fármacos em animais. A literatura disponível sobre o uso desses Inhalation anesthesia is widely used in veterinary anestésicos em animais está revisada neste artigo. medicine. New inhalation anesthetics that present less untoward effects, are more potent and produce a safe and easily changeable Palavras-chave: anestesia inalatória, sevoflurano, desflurano, anesthetic plane are desirable over the older agents presently xenônio. available. In this review some of the physical and chemical aspects of inhalation anesthesia is revisited. Because the agents used in inhalation anesthesia are gases or vapors, the physics of vaporization, delivery and administration of these agents should INTRODUCTION be understood. The two new inhalation anesthetics sevoflurane and desflurane, and the new anesthetic gas xenon have been used Inhalation anesthetics are used widely for in human beings for some time. In veterinary medicine there is a the anesthetic management of animals. They are lack of investigation and reports that assure the safety and clinical aspects of using them in animals. The information unique among the anesthetic drugs because they are available on the use of these new agents in animals is revised in administered, and in large part removed from the this article. body, via the lungs. Their popularity arises in part because their pharmacokinetic characteristics favor Key words: inhalation anesthesia, sevoflurane, desflurane, and xenon.
    [Show full text]